Evonik Industries posted its strongest quarterly result in four years on August 4, when the Essen-based specialty chemicals group reported second-quarter 2026 adjusted EBITDA of €630 million, a 24% increase on the €509 million recorded in Q2 2025. Group revenue climbed 11% year-on-year, driven by equal seven-percentage-point contributions from higher volumes and higher selling prices, partially offset by a two-percentage-point foreign exchange headwind. Chief Executive Christian Kullmann characterised the outcome as “the best quarter result in four years.”
The result came alongside a significant upgrade to full-year 2026 guidance. Evonik now targets adjusted EBITDA of €2.0-2.2 billion for the year, up from the previous range of €1.7-2.0 billion. H1 2026 adjusted EBITDA reached approximately €1.1 billion, meaning the guidance midpoint of €2.1 billion requires further acceleration in the second half, not merely a repetition of the H1 run rate.
Free cash flow swung from negative €211 million in Q2 2025 to positive €49 million in Q2 2026, a turnaround that CFO Michael Rauch linked to ongoing balance-sheet priorities: “We want to improve debt ratios to create more flexibility going forward.” The cash conversion rate reached approximately 40% on an annualised basis, in line with the company’s 2026 target.
Net income told a more qualified story, declining to €84 million from €120 million in the prior-year quarter. The gap between adjusted EBITDA performance and net income reflects restructuring charges accumulating under the “Evonik Tailor Made” transformation programme. That programme has removed approximately 700 positions since early 2026, working toward 2,800 reductions through 2026 and a further 3,200 planned for 2027-2029.
Advanced Technologies: crosslinkers and high-performance polymers outperform
Advanced Technologies - the segment covering specialty organics, high-performance polymers, crosslinkers, and related materials - delivered Q2 2026 sales of €1,647 million, up 9% year-on-year, and adjusted EBITDA of €333 million, a 25% improvement. The EBITDA margin widened from 17.6% to 20.2%.
Crosslinkers and high-performance polymers were cited as the standout performers within the segment. Crosslinkers - used in epoxy and polyurethane coating systems, adhesives, and reactive resin formulations - benefited from what Evonik described as favourable market momentum. High-performance polymers, which include specialty polyamides and engineering thermoplastics, recovered from a capacity-utilisation dip in the prior-year period that followed a major planned shutdown.
Both product lines sit within reactive and compounding chemistries where inline process monitoring is an established discipline: endpoint detection for crosslinking reactions, melt-quality control during continuous compounding, and composition verification in multi-component polymer blends are application areas addressed by inline spectroscopic analyzers. The segment’s margin expansion signals that specialty resin and polymer producers are running at higher utilisation rates - conditions that historically correlate with renewed investment in yield-improvement and quality-assurance instrumentation. Comparable dynamics surfaced in Q1 2026 capex signals from BASF, Dow, and LyondellBasell, where volume recovery preceded a tighter focus on process efficiency spending.
Custom Solutions: PU foam and coatings additives rebound
Custom Solutions - covering performance additives, care actives, and oil additives - reported Q2 2026 sales of €1,422 million (up 4%) and adjusted EBITDA of €271 million (up 7%), with the EBITDA margin firming to 19.1% from 18.6%.
Evonik attributed the advance to higher demand for additives used in polyurethane foams and consumer durables, alongside stronger business in additives for paints and coatings and in oil additives. Selling prices increased alongside volumes. The coatings and adhesives sectors draw from both the crosslinker recovery in Advanced Technologies and the additive recovery in Custom Solutions - a degree of coordinated demand pull that suggests the improvement is not confined to a single application vertical.
Animal Nutrition: price momentum and supply-chain dislocation
Animal Nutrition - principally Evonik’s methionine and broader amino-acid business - contributed sustained price momentum to H1 results, though volumes were slightly constrained by planned maintenance shutdowns. A secondary driver was supply-chain dislocation: uncertainty around Strait of Hormuz shipping routes benefited sourcing from producers operating outside the affected lanes, a tailwind Evonik flagged as having limited visibility beyond Q3 2026.
Amino-acid manufacturing at the scale and purity specifications Evonik operates - continuous fermentation, separation, and crystallisation - is one of the more process-analytics-intensive environments in specialty chemicals. Fermentation titre monitoring, downstream pH control, and crystalliser endpoint detection are standard applications for inline measurement. Sustained margin strength in this segment provides headroom for equipment maintenance and upgrade cycles that capital-constrained operations tend to defer.
What the recovery signals for process analytics buyers and vendors
Specialty chemicals margins drive two things relevant to the process analytics market: the financial capacity to authorise capital projects, and the operational pressure to maintain throughput with fewer people. Evonik’s Q2 results illustrate both dynamics simultaneously.
The 160-basis-point expansion in group EBITDA margin - from 14.5% to 16.2% - gives site managers in affected business lines stronger financial backing for instrumentation and monitoring upgrade proposals that may have been deferred through 2024 and 2025. Meanwhile, the Tailor Made programme’s targets of 6,000 total position reductions by 2029 create sustained pressure to maintain or grow output with smaller operating teams, a calculus that typically strengthens the case for automated inline quality control over manual at-line sampling.
Kullmann’s own framing is instructive: “We are witnessing a warm summer rain. But this does not change fundamental industry challenges.” Management is not reading the quarter as a cyclical all-clear. Structural efficiency investment - not capacity expansion - appears to be the strategic posture. That distinction matters to the process analytics market: upgrade and efficiency cycles tend to generate demand for inline analyzers and chemometric software, while expansion cycles generate demand for full greenfield instrumentation packages. Evonik’s current trajectory points toward the former.
The pattern is consistent with the H1 2026 mid-year review of process analytics end-market conditions, which tracked a comparable dynamic across European chemical operators entering a selective reinvestment phase. On the vendor side, the same end-market signals underpinned stronger services and consumables revenues in Thermo Fisher’s Q2 2026 analytical instruments results.
Evonik’s full Q2 2026 report, published August 4, is available via the company’s investor relations pages.